- Home
- KNSA vs PDI Comparison
KNSA vs PDI Comparison
Compare KNSA & PDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | PDI |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.0B |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KNSA | PDI |
|---|---|---|
| Price | $94.47 | $14.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $109.43 | N/A |
| AVG Volume (30 Days) | 925.9K | ★ 3.2M |
| Earning Date | 10-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $54.96 | N/A |
| Revenue Next Year | $24.16 | N/A |
| P/E Ratio | $84.32 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $37.02 | $13.73 |
| 52 Week High | $98.48 | $19.00 |
Technical Indicators
Market Signals| Indicator | KNSA | PDI |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 59.38 |
| Support Level | $72.76 | $13.96 |
| Resistance Level | $98.48 | $16.79 |
| Average True Range (ATR) | 5.49 | 0.23 |
| MACD | 0.78 | 0.08 |
| Stochastic Oscillator | 84.57 | 88.04 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is utilizing a dynamic asset allocation among multiple fixed income sectors in the international credit markets, including corporate debt (including, among other things, fixed-, variable- and floating-rate bonds, loans, mortgage-related and other asset-backed securities, government and sovereign debt, taxable municipal bonds and other fixed- variable- and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers.